PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CHTR vs. MRNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CHTR and MRNA is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

CHTR vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Charter Communications, Inc. (CHTR) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
12.27%
-72.20%
CHTR
MRNA

Key characteristics

Sharpe Ratio

CHTR:

-0.05

MRNA:

-1.05

Sortino Ratio

CHTR:

0.22

MRNA:

-1.82

Omega Ratio

CHTR:

1.03

MRNA:

0.77

Calmar Ratio

CHTR:

-0.03

MRNA:

-0.71

Martin Ratio

CHTR:

-0.11

MRNA:

-1.42

Ulcer Index

CHTR:

19.46%

MRNA:

46.36%

Daily Std Dev

CHTR:

40.78%

MRNA:

62.64%

Max Drawdown

CHTR:

-68.99%

MRNA:

-93.03%

Current Drawdown

CHTR:

-57.20%

MRNA:

-92.97%

Fundamentals

Market Cap

CHTR:

$49.96B

MRNA:

$13.11B

EPS

CHTR:

$32.33

MRNA:

-$5.86

PEG Ratio

CHTR:

0.35

MRNA:

0.00

Total Revenue (TTM)

CHTR:

$41.16B

MRNA:

$2.26B

Gross Profit (TTM)

CHTR:

$16.37B

MRNA:

$1.46B

EBITDA (TTM)

CHTR:

$16.13B

MRNA:

-$2.28B

Returns By Period

In the year-to-date period, CHTR achieves a 2.51% return, which is significantly higher than MRNA's -18.09% return.


CHTR

YTD

2.51%

1M

-0.04%

6M

12.27%

1Y

-5.32%

5Y*

-7.23%

10Y*

8.28%

MRNA

YTD

-18.09%

1M

-13.53%

6M

-72.20%

1Y

-65.84%

5Y*

9.20%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CHTR vs. MRNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHTR
The Risk-Adjusted Performance Rank of CHTR is 4141
Overall Rank
The Sharpe Ratio Rank of CHTR is 4242
Sharpe Ratio Rank
The Sortino Ratio Rank of CHTR is 3838
Sortino Ratio Rank
The Omega Ratio Rank of CHTR is 3737
Omega Ratio Rank
The Calmar Ratio Rank of CHTR is 4343
Calmar Ratio Rank
The Martin Ratio Rank of CHTR is 4343
Martin Ratio Rank

MRNA
The Risk-Adjusted Performance Rank of MRNA is 55
Overall Rank
The Sharpe Ratio Rank of MRNA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 33
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 33
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 77
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CHTR vs. MRNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Charter Communications, Inc. (CHTR) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CHTR, currently valued at -0.05, compared to the broader market-2.000.002.004.00-0.05-1.05
The chart of Sortino ratio for CHTR, currently valued at 0.22, compared to the broader market-4.00-2.000.002.004.006.000.22-1.82
The chart of Omega ratio for CHTR, currently valued at 1.03, compared to the broader market0.501.001.502.001.030.77
The chart of Calmar ratio for CHTR, currently valued at -0.03, compared to the broader market0.002.004.006.00-0.03-0.71
The chart of Martin ratio for CHTR, currently valued at -0.11, compared to the broader market-10.000.0010.0020.0030.00-0.11-1.42
CHTR
MRNA

The current CHTR Sharpe Ratio is -0.05, which is higher than the MRNA Sharpe Ratio of -1.05. The chart below compares the historical Sharpe Ratios of CHTR and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.20AugustSeptemberOctoberNovemberDecember2025
-0.05
-1.05
CHTR
MRNA

Dividends

CHTR vs. MRNA - Dividend Comparison

Neither CHTR nor MRNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CHTR vs. MRNA - Drawdown Comparison

The maximum CHTR drawdown since its inception was -68.99%, smaller than the maximum MRNA drawdown of -93.03%. Use the drawdown chart below to compare losses from any high point for CHTR and MRNA. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%AugustSeptemberOctoberNovemberDecember2025
-57.20%
-92.97%
CHTR
MRNA

Volatility

CHTR vs. MRNA - Volatility Comparison

The current volatility for Charter Communications, Inc. (CHTR) is 8.23%, while Moderna, Inc. (MRNA) has a volatility of 26.00%. This indicates that CHTR experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
8.23%
26.00%
CHTR
MRNA

Financials

CHTR vs. MRNA - Financials Comparison

This section allows you to compare key financial metrics between Charter Communications, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab